<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>Optimal phase II/III drug development planning with binary endpoint — optimal_binary • drugdevelopR</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet"><link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet"><script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Optimal phase II/III drug development planning with binary endpoint — optimal_binary"><meta name="description" content="The optimal_binary function of the drugdevelopR package enables
planning of phase II/III drug development programs with optimal sample size
allocation and go/no-go decision rules for binary endpoints. In this case,
the treatment effect is measured by the risk ratio (RR). The assumed true
treatment effects can be assumed to be fixed or modelled by a prior
distribution. The R Shiny application
prior visualizes the prior
distributions used in this package. Fast computing is enabled by parallel
programming."><meta property="og:description" content="The optimal_binary function of the drugdevelopR package enables
planning of phase II/III drug development programs with optimal sample size
allocation and go/no-go decision rules for binary endpoints. In this case,
the treatment effect is measured by the risk ratio (RR). The assumed true
treatment effects can be assumed to be fixed or modelled by a prior
distribution. The R Shiny application
prior visualizes the prior
distributions used in this package. Fast computing is enabled by parallel
programming."></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-light" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">1.0.2</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item"><a class="nav-link" href="../reference/index.html">Reference</a></li>
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-articles" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Articles</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-articles"><li><a class="dropdown-item" href="../articles/Introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a></li>
    <li><a class="dropdown-item" href="../articles/Package_validation.html">Package validation</a></li>
    <li><hr class="dropdown-divider"></li>
    <li><a class="dropdown-item" href="../articles/index.html">More articles...</a></li>
  </ul></li>
<li class="nav-item"><a class="nav-link" href="../news/index.html">Changelog</a></li>
      </ul><ul class="navbar-nav"><li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json"></form></li>
<li class="nav-item"><a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="GitHub"><span class="fa fab fa-github fa-lg"></span></a></li>
      </ul></div>


  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">

      <h1>Optimal phase II/III drug development planning with binary endpoint</h1>
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/v1.0.2-cran/R/optimal_binary.R" class="external-link"><code>R/optimal_binary.R</code></a></small>
      <div class="d-none name"><code>optimal_binary.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p>The <code>optimal_binary</code> function of the drugdevelopR package enables
planning of phase II/III drug development programs with optimal sample size
allocation and go/no-go decision rules for binary endpoints. In this case,
the treatment effect is measured by the risk ratio (RR). The assumed true
treatment effects can be assumed to be fixed or modelled by a prior
distribution. The R Shiny application
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">prior</a> visualizes the prior
distributions used in this package. Fast computing is enabled by parallel
programming.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-usage">Usage<a class="anchor" aria-label="anchor" href="#ref-usage"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span><span class="fu">optimal_binary</span><span class="op">(</span></span>
<span>  <span class="va">w</span>,</span>
<span>  <span class="va">p0</span>,</span>
<span>  <span class="va">p11</span>,</span>
<span>  <span class="va">p12</span>,</span>
<span>  <span class="va">in1</span>,</span>
<span>  <span class="va">in2</span>,</span>
<span>  <span class="va">n2min</span>,</span>
<span>  <span class="va">n2max</span>,</span>
<span>  <span class="va">stepn2</span>,</span>
<span>  <span class="va">rrgomin</span>,</span>
<span>  <span class="va">rrgomax</span>,</span>
<span>  <span class="va">steprrgo</span>,</span>
<span>  <span class="va">alpha</span>,</span>
<span>  <span class="va">beta</span>,</span>
<span>  <span class="va">c2</span>,</span>
<span>  <span class="va">c3</span>,</span>
<span>  <span class="va">c02</span>,</span>
<span>  <span class="va">c03</span>,</span>
<span>  K <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  N <span class="op">=</span> <span class="cn">Inf</span>,</span>
<span>  S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,</span>
<span>  steps1 <span class="op">=</span> <span class="fl">1</span>,</span>
<span>  stepm1 <span class="op">=</span> <span class="fl">0.95</span>,</span>
<span>  stepl1 <span class="op">=</span> <span class="fl">0.85</span>,</span>
<span>  <span class="va">b1</span>,</span>
<span>  <span class="va">b2</span>,</span>
<span>  <span class="va">b3</span>,</span>
<span>  gamma <span class="op">=</span> <span class="fl">0</span>,</span>
<span>  fixed <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  skipII <span class="op">=</span> <span class="cn">FALSE</span>,</span>
<span>  num_cl <span class="op">=</span> <span class="fl">1</span></span>
<span><span class="op">)</span></span></code></pre></div>
    </div>

    <div class="section level2">
    <h2 id="arguments">Arguments<a class="anchor" aria-label="anchor" href="#arguments"></a></h2>


<dl><dt id="arg-w">w<a class="anchor" aria-label="anchor" href="#arg-w"></a></dt>
<dd><p>weight for <a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">mixture prior distribution</a></p></dd>


<dt id="arg-p-">p0<a class="anchor" aria-label="anchor" href="#arg-p-"></a></dt>
<dd><p>assumed true rate of control group, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt id="arg-p-">p11<a class="anchor" aria-label="anchor" href="#arg-p-"></a></dt>
<dd><p>assumed true rate of treatment group, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt id="arg-p-">p12<a class="anchor" aria-label="anchor" href="#arg-p-"></a></dt>
<dd><p>assumed true rate of treatment group, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt id="arg-in-">in1<a class="anchor" aria-label="anchor" href="#arg-in-"></a></dt>
<dd><p>amount of information for <code>p11</code> in terms of sample size, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt id="arg-in-">in2<a class="anchor" aria-label="anchor" href="#arg-in-"></a></dt>
<dd><p>amount of information for <code>p12</code> in terms of sample size, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt id="arg-n-min">n2min<a class="anchor" aria-label="anchor" href="#arg-n-min"></a></dt>
<dd><p>minimal total sample size for phase II; must be an even number</p></dd>


<dt id="arg-n-max">n2max<a class="anchor" aria-label="anchor" href="#arg-n-max"></a></dt>
<dd><p>maximal total sample size for phase II, must be an even number</p></dd>


<dt id="arg-stepn-">stepn2<a class="anchor" aria-label="anchor" href="#arg-stepn-"></a></dt>
<dd><p>step size for the optimization over n2; must be an even number</p></dd>


<dt id="arg-rrgomin">rrgomin<a class="anchor" aria-label="anchor" href="#arg-rrgomin"></a></dt>
<dd><p>minimal threshold value for the go/no-go decision rule</p></dd>


<dt id="arg-rrgomax">rrgomax<a class="anchor" aria-label="anchor" href="#arg-rrgomax"></a></dt>
<dd><p>maximal threshold value for the go/no-go decision rule</p></dd>


<dt id="arg-steprrgo">steprrgo<a class="anchor" aria-label="anchor" href="#arg-steprrgo"></a></dt>
<dd><p>step size for the optimization over RRgo</p></dd>


<dt id="arg-alpha">alpha<a class="anchor" aria-label="anchor" href="#arg-alpha"></a></dt>
<dd><p>one-sided significance level</p></dd>


<dt id="arg-beta">beta<a class="anchor" aria-label="anchor" href="#arg-beta"></a></dt>
<dd><p>type II error rate; i.e. <code>1 - beta</code> is the power for calculation of the number of events for phase III</p></dd>


<dt id="arg-c-">c2<a class="anchor" aria-label="anchor" href="#arg-c-"></a></dt>
<dd><p>variable per-patient cost for phase II in 10^5 $</p></dd>


<dt id="arg-c-">c3<a class="anchor" aria-label="anchor" href="#arg-c-"></a></dt>
<dd><p>variable per-patient cost for phase III in 10^5 $</p></dd>


<dt id="arg-c-">c02<a class="anchor" aria-label="anchor" href="#arg-c-"></a></dt>
<dd><p>fixed cost for phase II in 10^5 $</p></dd>


<dt id="arg-c-">c03<a class="anchor" aria-label="anchor" href="#arg-c-"></a></dt>
<dd><p>fixed cost for phase III in 10^5 $</p></dd>


<dt id="arg-k">K<a class="anchor" aria-label="anchor" href="#arg-k"></a></dt>
<dd><p>constraint on the costs of the program, default: Inf, e.g. no constraint</p></dd>


<dt id="arg-n">N<a class="anchor" aria-label="anchor" href="#arg-n"></a></dt>
<dd><p>constraint on the total expected sample size of the program, default: Inf, e.g. no constraint</p></dd>


<dt id="arg-s">S<a class="anchor" aria-label="anchor" href="#arg-s"></a></dt>
<dd><p>constraint on the expected probability of a successful program, default: -Inf, e.g. no constraint</p></dd>


<dt id="arg-steps-">steps1<a class="anchor" aria-label="anchor" href="#arg-steps-"></a></dt>
<dd><p>lower boundary for effect size category "small" in RR scale, default: 1</p></dd>


<dt id="arg-stepm-">stepm1<a class="anchor" aria-label="anchor" href="#arg-stepm-"></a></dt>
<dd><p>lower boundary for effect size category "medium" in RR scale = upper boundary for effect size category "small" in RR scale, default: 0.95</p></dd>


<dt id="arg-stepl-">stepl1<a class="anchor" aria-label="anchor" href="#arg-stepl-"></a></dt>
<dd><p>lower boundary for effect size category "large" in RR scale = upper boundary for effect size category "medium" in RR scale, default: 0.85</p></dd>


<dt id="arg-b-">b1<a class="anchor" aria-label="anchor" href="#arg-b-"></a></dt>
<dd><p>expected gain for effect size category "small"</p></dd>


<dt id="arg-b-">b2<a class="anchor" aria-label="anchor" href="#arg-b-"></a></dt>
<dd><p>expected gain for effect size category "medium"</p></dd>


<dt id="arg-b-">b3<a class="anchor" aria-label="anchor" href="#arg-b-"></a></dt>
<dd><p>expected gain for effect size category "large"</p></dd>


<dt id="arg-gamma">gamma<a class="anchor" aria-label="anchor" href="#arg-gamma"></a></dt>
<dd><p>to model different populations in phase II and III choose <code>gamma != 0</code>, default: 0, see
<a href="https://web.imbi.uni-heidelberg.de/prior/" class="external-link">here</a>
for details</p></dd>


<dt id="arg-fixed">fixed<a class="anchor" aria-label="anchor" href="#arg-fixed"></a></dt>
<dd><p>choose if true treatment effects are fixed or random, if TRUE p11 is used as fixed effect for p1</p></dd>


<dt id="arg-skipii">skipII<a class="anchor" aria-label="anchor" href="#arg-skipii"></a></dt>
<dd><p>skipII choose if skipping phase II is an option, default: FALSE;
if TRUE, the program calculates the expected utility for the case when phase
II is skipped and compares it to the situation when phase II is not skipped.
The results are then returned as a two-row data frame, <code>res[1, ]</code>
being the results when including phase II and <code>res[2, ]</code> when skipping phase II.
<code>res[2, ]</code> has an additional parameter, <code>res[2, ]$median_prior_RR</code>, which is
the assumed effect size used for planning the phase III study when the
phase II is skipped.</p></dd>


<dt id="arg-num-cl">num_cl<a class="anchor" aria-label="anchor" href="#arg-num-cl"></a></dt>
<dd><p>number of clusters used for parallel computing, default: 1</p></dd>

</dl></div>
    <div class="section level2">
    <h2 id="value">Value<a class="anchor" aria-label="anchor" href="#value"></a></h2>
    <p>The output of the function is a <code>data.frame</code> object containing the optimization results:</p><dl><dt>RRgo</dt>
<dd><p>optimal threshold value for the decision rule to go to phase III</p></dd>
<dt>n2</dt>
<dd><p>total sample size for phase II; rounded to the next even natural number</p></dd>

<dt>n3</dt>
<dd><p>total sample size for phase III; rounded to the next even natural number</p></dd>

<dt>n</dt>
<dd><p>total sample size in the program; n = n2 + n3</p></dd>

<dt>K</dt>
<dd><p>maximal costs of the program (i.e. the cost constraint, if it is set or the sum K2+K3 if no cost constraint is set)</p></dd>

<dt>pgo</dt>
<dd><p>probability to go to phase III</p></dd>

<dt>sProg</dt>
<dd><p>probability of a successful program</p></dd>
<dt>sProg1</dt>
<dd><p>probability of a successful program with "small" treatment effect in phase III</p></dd>

<dt>sProg2</dt>
<dd><p>probability of a successful program with "medium" treatment effect in phase III</p></dd>

<dt>sProg3</dt>
<dd><p>probability of a successful program with "large" treatment effect in phase III</p></dd>
<dt>K2</dt>
<dd><p>expected costs for phase II</p></dd>

<dt>K3</dt>
<dd><p>expected costs for phase III</p></dd>

</dl><p>and further input parameters. Taking <code>cat(comment())</code> of the
data frame lists the used optimization sequences, start and
finish time of the optimization procedure. The attribute
<code>attr(,"trace")</code> returns the utility values of all parameter
combinations visited during optimization.</p>
    </div>
    <div class="section level2">
    <h2 id="references">References<a class="anchor" aria-label="anchor" href="#references"></a></h2>
    <p>IQWiG (2016). Allgemeine Methoden. Version 5.0, 10.07.2016, Technical Report. Available at <a href="https://www.iqwig.de/ueber-uns/methoden/methodenpapier/" class="external-link">https://www.iqwig.de/ueber-uns/methoden/methodenpapier/</a>, last access 15.05.19.</p>
    </div>

    <div class="section level2">
    <h2 id="ref-examples">Examples<a class="anchor" aria-label="anchor" href="#ref-examples"></a></h2>
    <div class="sourceCode"><pre class="sourceCode r"><code><span class="r-in"><span><span class="co"># Activate progress bar (optional)</span></span></span>
<span class="r-in"><span><span class="kw">if</span> <span class="op">(</span><span class="cn">FALSE</span><span class="op">)</span> <span class="op">{</span> <span class="co"># \dontrun{</span></span></span>
<span class="r-in"><span><span class="fu">progressr</span><span class="fu">::</span><span class="fu"><a href="https://progressr.futureverse.org/reference/handlers.html" class="external-link">handlers</a></span><span class="op">(</span>global <span class="op">=</span> <span class="cn">TRUE</span><span class="op">)</span></span></span>
<span class="r-in"><span><span class="op">}</span> <span class="co"># }</span></span></span>
<span class="r-in"><span><span class="co"># Optimize</span></span></span>
<span class="r-in"><span><span class="co"># \donttest{</span></span></span>
<span class="r-in"><span><span class="fu">optimal_binary</span><span class="op">(</span>w <span class="op">=</span> <span class="fl">0.3</span>,                             <span class="co"># define parameters for prior</span></span></span>
<span class="r-in"><span>  p0 <span class="op">=</span> <span class="fl">0.6</span>, p11 <span class="op">=</span>  <span class="fl">0.3</span>, p12 <span class="op">=</span> <span class="fl">0.5</span>,</span></span>
<span class="r-in"><span>  in1 <span class="op">=</span> <span class="fl">30</span>, in2 <span class="op">=</span> <span class="fl">60</span>,                               <span class="co"># (https://web.imbi.uni-heidelberg.de/prior/)</span></span></span>
<span class="r-in"><span>  n2min <span class="op">=</span> <span class="fl">20</span>, n2max <span class="op">=</span> <span class="fl">100</span>, stepn2 <span class="op">=</span> <span class="fl">4</span>,              <span class="co"># define optimization set for n2</span></span></span>
<span class="r-in"><span>  rrgomin <span class="op">=</span> <span class="fl">0.7</span>, rrgomax <span class="op">=</span> <span class="fl">0.9</span>, steprrgo <span class="op">=</span> <span class="fl">0.05</span>,    <span class="co"># define optimization set for RRgo</span></span></span>
<span class="r-in"><span>  alpha <span class="op">=</span> <span class="fl">0.025</span>, beta <span class="op">=</span> <span class="fl">0.1</span>,                        <span class="co"># drug development planning parameters</span></span></span>
<span class="r-in"><span>  c2 <span class="op">=</span> <span class="fl">0.75</span>, c3 <span class="op">=</span> <span class="fl">1</span>, c02 <span class="op">=</span> <span class="fl">100</span>, c03 <span class="op">=</span> <span class="fl">150</span>,          <span class="co"># fixed and variable costs for phase II/III,</span></span></span>
<span class="r-in"><span>  K <span class="op">=</span> <span class="cn">Inf</span>, N <span class="op">=</span> <span class="cn">Inf</span>, S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,                       <span class="co"># set constraints</span></span></span>
<span class="r-in"><span>  steps1 <span class="op">=</span> <span class="fl">1</span>,                                       <span class="co"># define lower boundary for "small"</span></span></span>
<span class="r-in"><span>  stepm1 <span class="op">=</span> <span class="fl">0.95</span>,                                    <span class="co"># "medium"</span></span></span>
<span class="r-in"><span>  stepl1 <span class="op">=</span> <span class="fl">0.85</span>,                                    <span class="co"># and "large" treatment effect size categories</span></span></span>
<span class="r-in"><span>  b1 <span class="op">=</span> <span class="fl">1000</span>, b2 <span class="op">=</span> <span class="fl">2000</span>, b3 <span class="op">=</span> <span class="fl">3000</span>,                  <span class="co"># define expected benefits</span></span></span>
<span class="r-in"><span>  gamma <span class="op">=</span> <span class="fl">0</span>,                                        <span class="co"># population structures in phase II/III</span></span></span>
<span class="r-in"><span>  fixed <span class="op">=</span> <span class="cn">FALSE</span>,                                    <span class="co"># true treatment effects are fixed/random</span></span></span>
<span class="r-in"><span>  skipII <span class="op">=</span> <span class="cn">FALSE</span>,                                   <span class="co"># choose if skipping phase II is an option</span></span></span>
<span class="r-in"><span>  num_cl <span class="op">=</span> <span class="fl">2</span><span class="op">)</span>                                       <span class="co"># number of cores for parallelized computing</span></span></span>
<span class="r-out co"><span class="r-pr">#&gt;</span> Optimization result:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Utility: 574.64</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Sample size:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 100, phase III: 222, total: 322</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Probability to go to phase III: 0.66</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Total cost:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 175, phase III: 321, cost constraint: Inf</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Fixed cost:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 100, phase III: 150</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Variable cost per patient:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    phase II: 0.75, phase III: 1</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Effect size categories (expected gains):</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>   small: 1 (1000), medium: 0.95 (2000), large: 0.85 (3000)</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Success probability: 0.44</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Joint probability of success and observed effect of size ... in phase III:</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    small: 0.06, medium: 0.13, large: 0.25</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Significance level: 0.025</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Targeted power: 0.9</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Decision rule threshold: 0.85 [RRgo] </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Parameters of the prior distribution: </span>
<span class="r-out co"><span class="r-pr">#&gt;</span>    p0: 0.6,  p11: 0.3, p12: 0.5, in1: 30, in2: 60, w: 0.3</span>
<span class="r-out co"><span class="r-pr">#&gt;</span>  Treatment effect offset between phase II and III: 0 [gamma] </span>
<span class="r-in"><span>  <span class="co"># }</span></span></span>
</code></pre></div>
    </div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p>Developed by Stella Erdmann, Johannes Cepicka, Marietta Kirchner, Meinhard Kieser, Lukas D. Sauer.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.</p>
</div>

    </footer></div>





  </body></html>

